Glenmark Pharmaceuticals Ltd said its Swiss arm has entered into an exclusive licensing agreement with Lotus International Pte Ltd for commercialising its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.
- How to choose the Best Stocks for Intraday F&O trading in India?
- Vedanta Outlook for the Week (May 06, 2024 – May 10, 2024)
- Tata Steel Outlook for the Week (May 06, 2024 – May 10, 2024)
- PFC Outlook for the Week (May 06, 2024 – May 10, 2024)
- Piramal Enterprises Outlook for the Week (May 06, 2024 – May 10, 2024)
Under the agreement signed between Glenmark Specialty SA and the wholly-owned subsidiary of Lotus Pharmaceutical Co, Ltd (Lotus), Glenmark will be responsible for the manufacturing and supply of Ryaltris.
On the other hand Lotus will be responsible for its commercialization subject to receipt of regulatory approvals, in these markets, the company said in a statement.